Not only Gil Kaplan has presented the global epidemiological trends in a fantastic way, but he has also given us hope that, despite the challenges, we can curb the rising trends in #IBD if we work together.
Speechless—thank you, Gil! 🙏
The IFX study, whilst it has its limitations (small N), has a bigger delta with placebo at week 52. The VDZ had an unusual dosing protocol (straight to maintenance) with endpoints looking inferior to IFX already at week 26. PK? I know we shouldn't compare non-H2H studies but in this instance....
Hi Liz! Hope you are keeping well. It's much nicer here on bluesky!
Great work as always! Just to add, dosing for risankizumab for UC and mirikizumab for Crohn's are a bit different. Guselkumab is the same for both. Also I suspect SC guselkumab for induction will be an option soon.
ECCO'25 deadline tomorrow! Eleventh hour submissions in progress....
IBD doc from the 🇦🇪 and 🇬🇧
